loading
Editas Medicine Inc stock is traded at $2.80, with a volume of 1.46M. It is up +2.56% in the last 24 hours and down -16.67% over the past month. Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.73
Open:
$2.74
24h Volume:
1.46M
Relative Volume:
0.59
Market Cap:
$251.78M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.9722
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-7.59%
1M Performance:
-16.67%
6M Performance:
+45.83%
1Y Performance:
-26.12%
1-Day Range:
Value
$2.7324
$2.921
1-Week Range:
Value
$2.60
$3.08
52-Week Range:
Value
$0.9101
$4.12

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Name
Editas Medicine Inc
Name
Phone
617-401-9000
Name
Address
11 HURLEY ST., CAMBRIDGE, MA
Name
Employee
226
Name
Twitter
@editasmed
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
EDIT's Discussions on Twitter

Compare EDIT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
EDIT
Editas Medicine Inc
2.80 245.48M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-28-25 Initiated H.C. Wainwright Buy
Dec-16-24 Downgrade JP Morgan Neutral → Underweight
Dec-13-24 Downgrade Chardan Capital Markets Buy → Neutral
Dec-13-24 Downgrade Stifel Buy → Hold
Dec-13-24 Downgrade Truist Buy → Hold
Dec-11-24 Downgrade Wells Fargo Overweight → Equal Weight
Nov-25-24 Downgrade BofA Securities Buy → Underperform
Nov-06-24 Upgrade Evercore ISI In-line → Outperform
Nov-04-24 Downgrade Raymond James Outperform → Mkt Perform
Aug-08-24 Upgrade BofA Securities Neutral → Buy
May-09-24 Upgrade Morgan Stanley Underweight → Equal-Weight
Oct-24-23 Upgrade Citigroup Neutral → Buy
Oct-18-23 Upgrade JP Morgan Underweight → Neutral
Oct-17-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-29-23 Upgrade Stifel Hold → Buy
Jun-12-23 Upgrade Raymond James Mkt Perform → Outperform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-13-22 Initiated Citigroup Neutral
Dec-06-22 Resumed Credit Suisse Neutral
Nov-18-22 Downgrade Credit Suisse Outperform → Neutral
Nov-18-22 Downgrade Oppenheimer Outperform → Perform
Sep-29-22 Initiated BofA Securities Neutral
Oct-19-21 Initiated SVB Leerink Mkt Perform
Sep-24-21 Initiated Stifel Hold
Sep-10-21 Upgrade Oppenheimer Perform → Outperform
Aug-09-21 Upgrade Truist Hold → Buy
Aug-05-21 Upgrade Evercore ISI Underperform → Outperform
Jun-04-21 Resumed Robert W. Baird Outperform
May-04-21 Initiated RBC Capital Mkts Sector Perform
Apr-16-21 Initiated Goldman Sell
Mar-22-21 Initiated Credit Suisse Outperform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-26-21 Downgrade Truist Buy → Hold
Jan-19-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-07-21 Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20 Upgrade Wells Fargo Equal Weight → Overweight
Nov-03-20 Initiated Robert W. Baird Underperform
Jun-18-20 Resumed SunTrust Buy
Feb-21-20 Initiated Wells Fargo Equal Weight
Apr-12-19 Initiated Evercore ISI Outperform
Oct-10-18 Initiated Guggenheim Neutral
Sep-21-18 Initiated Raymond James Outperform
May-15-18 Reiterated Chardan Capital Markets Buy
Feb-13-18 Initiated CLSA Underperform
Jan-23-18 Upgrade SunTrust Hold → Buy
Jul-14-17 Initiated SunTrust Hold
Mar-28-17 Initiated Chardan Capital Markets Buy
Aug-10-16 Upgrade Jefferies Hold → Buy
Jun-02-16 Initiated Jefferies Hold
Feb-29-16 Initiated JMP Securities Mkt Outperform
Feb-29-16 Initiated JP Morgan Neutral
Feb-29-16 Initiated Morgan Stanley Equal-Weight
View All

Editas Medicine Inc Stock (EDIT) Latest News

pulisher
Aug 20, 2025

Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Editas Medicine Inc. Moves Into Overbought Range Analysts CautiousPrice Action & Stepwise Swing Trade Plans - beatles.ru

Aug 20, 2025
pulisher
Aug 19, 2025

Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

Editas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00 at Robert W. Baird - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Short interest data insights for Editas Medicine Inc.2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Intraday pattern recognizer results for Editas Medicine Inc.July 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to recover losses in Editas Medicine Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Ranking Editas Medicine Inc. among high performing stocks via toolsJuly 2025 Technicals & Fast Moving Trade Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to build a custom watchlist for Editas Medicine Inc.Weekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Trend analysis for Editas Medicine Inc. this weekWeekly Trend Recap & Comprehensive Market Scan Insights - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

What makes Editas Medicine Inc. stock price move sharplyTrend Reversal & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is Editas Medicine Inc. showing signs of accumulationMarket Growth Review & High Accuracy Buy Signal Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

HC Wainwright Boosts Editas Medicine Price Target to $5.00, Analysts Predict 22.47% Upside - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine's Q2 Earnings Boost Stock Price 34% Amid Plans to Nominate First In Vivo Development Candidate in September - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street Zen - Defense World

Aug 16, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & Free Verified High Yield Trade Plans - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

What drives Editas Medicine Inc.’s stock priceProduct Launch & Daily Technical Stock Forecast Reports - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

Why Editas Medicine Stock Was Skyrocketing This Week - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress - Investing.com Canada

Aug 15, 2025
pulisher
Aug 15, 2025

Editas Medicine: HC Wainwright Raises PT to $5, Maintains Buy Rating - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Robert W. Baird Forecasts Strong Price Appreciation for Editas Medicine (NASDAQ:EDIT) Stock - Defense World

Aug 15, 2025
pulisher
Aug 14, 2025

How Interest Rate Changes Impact Editas Medicine Inc. Stock PerformanceMarket Movement Recap & Daily Profit Focused Stock Screening - Newser

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Rebound Backed by Sentiment Shift2025 Price Action Summary & Consistent Income Trade Recommendations - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Applications Of Genetic Engineering Market is Booming Worldwide | Editas Medicine , Intellia Therapeutics - newstrail.com

Aug 14, 2025
pulisher
Aug 14, 2025

Editas Medicine Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Weekly Chart Analysis and Trade Guides - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 13, 2025

Editas Medicine Reports Q2 2025 Progress and Financials - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine’s SWOT analysis: gene editing stock faces challenges, opportunities - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $6 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine shares surge 28.87% intraday after strong Q2 earnings and positive analyst ratings. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Surges 34% on Q2 Momentum and Strategic Milestones – What’s Fueling the Biotech Rally? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Can Editas Medicine Inc. Regain Momentum After BreakdownQuarterly Profit Review & Precise Buy Zone Identification - 선데이타임즈

Aug 13, 2025
pulisher
Aug 13, 2025

Baird raises Editas Medicine stock price target to $6 on pipeline progress - Investing.com Nigeria

Aug 13, 2025
pulisher
Aug 13, 2025

Editas: Q2 Earnings Snapshot - Greenwich Time

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

What high frequency data says about Editas Medicine Inc.2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine 2025 Q2 Earnings Narrows Losses Amid Revenue Surge - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewswire

Aug 13, 2025
pulisher
Aug 12, 2025

Editas Medicine's Q2 Performance: Assessing Progress Amid Financial Challenges - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Misses Expectations But Stays Focused On The Future - Finimize

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine earnings missed by $0.23, revenue topped estimates - Investing.com Canada

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Inc Q2 2025 Earnings: Revenue Soars to $3.6M, Beating Estimates; EPS Misses at -$0.63 - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine posts Q2 net loss of $53.2 mln - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine Reports Q2 2025 Results, Advances Gene Editing Programs - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Editas Medicine narrows losses as Bristol Myers Squibb partnership hits key milestone - Stock Titan

Aug 12, 2025

Editas Medicine Inc Stock (EDIT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Editas Medicine Inc Stock (EDIT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Jul 31 '25
Sale
2.49
5,121
12,757
64,398
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):